{"id":582005,"date":"2022-01-13T19:28:02","date_gmt":"2022-01-13T19:28:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=582005"},"modified":"2022-01-13T19:28:02","modified_gmt":"2022-01-13T19:28:02","slug":"aptamers-market-worth-342-million-by-2026-key-players-are-aptamer-group-uk-raptamer-discovery-group-us","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/aptamers-market-worth-342-million-by-2026-key-players-are-aptamer-group-uk-raptamer-discovery-group-us_582005.html","title":{"rendered":"Aptamers Market worth $342 million by 2026 – Key Players are Aptamer Group (UK), Raptamer Discovery Group (US)"},"content":{"rendered":"
\n
\"Aptamers<\/a><\/div>\n
\n
Some of the key players operating in the aptamers market include Aptamer Group (UK), Raptamer Discovery Group (US), SomaLogic Inc., (US), Aptamer Sciences, Inc. (South Korea), Aptagen, LLC (US), Maravai Lifesciences (US), Kaneka Corporation (Japan), NeoVentures Biotechnology Inc. (Canada), Aptus Biotech (Spain).<\/div>\n<\/div>\n<\/div>\n
Aptamers Market Research Report Gives in Detailed Analysis of Industry Segments, Opportunities, Growth and Size That Will Help Your Business Grow.<\/div>\n

ccording to the new market research report “Aptamers Market<\/a> by Product Type (DNA, RNA, XNA), Technology (SELEX), Application (Therapeutics, Diagnostics, R&D), End Users (Pharmaceutical & Biotechnology Companies, Academic & Government Research Institutes, CROs) – Global Forecast to 2026″<\/strong>, published by MarketsandMarkets™, the global market was valued at an estimated USD 151 million in 2021 and is projected to reach USD 342 million by 2026, at a CAGR of 17.7% during the forecast period.<\/p>\n

Browse in-depth TOC on <\/em>“Aptamers Market”<\/strong><\/p>\n

196 – Tables<\/strong>
38 – Figures<\/strong>
183 – Pages<\/strong><\/strong><\/p>\n

Download PDF Brochure: <\/strong>https:\/\/www.marketsandmarkets.com\/pdfdownloadNew.asp?id=1167<\/a><\/p>\n

Growth of aptamers market is attributed to factors such as increase in number of clinical trials for development of aptamer-based therapeutics, increase in awareness about advantages of aptamers as compared to antibodies, rising investment in pharmaceutical R&D, and rising prevalence of chronic and rare diseases to increase the demand for aptamer-based therapeutics and diagnostics.<\/p>\n

Growth in the venture capital funding for research on aptamers and growing collaborations with research institutes and pharmaceutical companies are also expected to offer a wide range of growth opportunities to players in the market. On the other hand, low market acceptance as compared to antibodies is likely to restrain the market growth while shortage of skilled & trained professionals may challenge market growth to a certain extent.<\/p>\n

Lower production cost and higher stability will drive the DNA-based aptamers segment growth<\/strong><\/p>\n

Based on type, the aptamers market is segmented into DNA aptamers, XNA aptamers, and RNA aptamers. The DNA-based aptamers segment dominated the market in 2020. The large share of this segment is attributed to their lower production cost and higher stability compared to other nucleic acid-based aptamers and the wide availability of DNA aptamers.<\/p>\n

Request Sample Pages: <\/strong>https:\/\/www.marketsandmarkets.com\/requestsampleNew.asp?id=1167<\/a><\/p>\n

Others segment is expected to witness the highest CAGR during the forecast period<\/strong><\/p>\n

Based on technology, the aptamers market is segmented into SELEX and other technologies. The SELEX technology segment dominated the market in 2020. The segment accounts for a large share of the aptamers market as SELEX is one of the most widely used technologies. The other technologies segment is expected to register the highest CAGR during the forecast period due to the increasing focus on developing technologies for aptamer selection.<\/p>\n

North America was the largest regional market for aptamers market in 2020<\/strong><\/p>\n

The global aptamers market is segmented into five major regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2020, North America accounted for the largest share of the market. The largest share of North America is attributed to the availability of funds to develop innovative technologies, the presence of prominent market players, and growing collaborations among companies.<\/p>\n

Speak to Analyst<\/strong>: https:\/\/www.marketsandmarkets.com\/speaktoanalystNew.asp?id=1167<\/a><\/p>\n

Some of the prominent players operating in this market include Aptamer Group (UK), Raptamer Discovery Group (US), SomaLogic Inc. (US), Aptamer Sciences, Inc. (South Korea) and Aptagen, LLC (US).<\/p>\n

Media Contact<\/span>
Company Name:<\/strong> MarketsandMarkets<\/a>
Contact Person:<\/strong> Mr. Aashish Mehra
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> 18886006441
Address:<\/strong>630 Dundee Road Suite 430
City:<\/strong> Northbrook
State:<\/strong> IL 60062
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.marketsandmarkets.com\/Market-Reports\/aptamers-technology-market-1167.html<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

Some of the key players operating in the aptamers market include Aptamer Group (UK), Raptamer Discovery Group (US), SomaLogic Inc., (US), Aptamer Sciences, Inc. (South Korea), Aptagen, LLC (US), Maravai Lifesciences (US), Kaneka Corporation (Japan), NeoVentures Biotechnology Inc. (Canada), Aptus … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,406,403,404],"tags":[],"class_list":["post-582005","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Pharmaceuticals-Biotech","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/582005","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=582005"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/582005\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=582005"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=582005"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=582005"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}